Vyxeos liposomal

Active substance daunorubicin and cytarabine
Holder Bionical Limited T/A Bionical Emas
Status closed
Indication Newly diagnosed, treatment-related acute myeloid Leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
Public documents Approbation
  Information for the patient
  Informed consent
Last update 24/11/2022

 

Last updated on 13/02/2024